Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06624176 · ClinicalTrials.gov registry record · NA

ShotBlocker During Intramuscular Injection Randomized Control Trial

A NA study of Neonatal Pain, sponsored by Lauren Fortier.

Recruiting
Registry status
NA
Development phase
200
Enrollment target
1
Study location

NCT06624176 is a NA study of Neonatal Pain that is actively recruiting participants, run by Lauren Fortier. The registered enrollment target is 200 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06624176, a NA study of Neonatal Pain, is actively recruiting participants, sponsored by Lauren Fortier.

RECRUITING
Registry status
NA
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

The objective of this trial is to evaluate the effect of Bionix ShotBlocker on pain of injection of the first Hepatitis B vaccine in healthy newborns. ShotBlocker is a pain reducing tool used in babies, children, and adults for injections. Swaddling during the injection and administration of oral sucrose prior to the injection are established standards of care for painful procedures in neonates. The investigators hypothesize that the use of ShotBlocker in addition to swaddling and oral sucrose administration will lessen the pain response.

Conditions Studied

Interventions

  • DEVICE Bionix ShotBlocker
  • OTHER Swaddling
  • OTHER Sucrose administration
  • OTHER Masimo Rad-97 Oximeter probe

Study Locations (1)

Massachusetts

  • UMass Memorial Medical Center- Memorial Campus - Worcester

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2024-01-10
Est. Completion 2026-08-01
Phase NA

Sponsor

Lauren Fortier

1 total trials

What the Registry Record Tells You About NCT06624176

The ClinicalTrials.gov registry entry for NCT06624176 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lauren Fortier, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neonatal Pain appearing as the primary indexed condition, and to 4 interventions - of which Bionix ShotBlocker is the first listed.

NCT06624176 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06624176 about?

NCT06624176 is a clinical study titled "ShotBlocker During Intramuscular Injection Randomized Control Trial". The objective of this trial is to evaluate the effect of Bionix ShotBlocker on pain of injection of the first Hepatitis B vaccine in healthy newborns. ShotBlocker is a pain reducing tool used in babies, children, and adults for injections. Swaddling during the injection and administration of oral su...

What is the current status of trial NCT06624176?

This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2024-01-10. Estimated completion is 2026-08-01.

What conditions does trial NCT06624176 study?

This clinical trial studies the following conditions: Neonatal Pain.

What interventions are being tested in trial NCT06624176?

The interventions under investigation include: Bionix ShotBlocker (DEVICE), Swaddling (OTHER), Sucrose administration (OTHER), Masimo Rad-97 Oximeter probe (OTHER).

Who is sponsoring clinical trial NCT06624176?

This trial is sponsored by Lauren Fortier, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06624176 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.